Mesa Laboratories (MLAB) CAO Elizabeth Sells 233 Shares
Crennen Lyndsey Elizabeth, CAO of Mesa Laboratories, sold 233 shares on June 18, 2026, amid other insider transactions.
Reviewed by automated data checks against the source filing. How we make and check alerts
Crennen Lyndsey Elizabeth, CAO at Mesa Laboratories, Inc. ($MLAB), sold 233 shares on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MLAB is up 3.2% after 1 week, up 1.6% after 1 month and up 28.9% to date (from the $94.98 close on Jun 18, 2026).
MLAB
Mesa Laboratories, Inc.
Key Points
- Crennen Lyndsey Elizabeth sold 233 shares of Mesa Laboratories, Inc. on June 18, 2026, with the stock trading at $93.23 at the time.
- On the same day, Elizabeth also bought 263 shares valued at about $25,011, suggesting mixed activity among insiders.
- Analysts remain cautious, with Wells Fargo maintaining an Equal-Weight rating and a price target of $110.00 as of August 14, 2026.
Get $MLAB trade alerts by text
We text you when insiders, Congress or big funds trade $MLAB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Mesa Laboratories, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Mesa Laboratories, Inc.
Crennen Lyndsey Elizabeth, the Chief Accounting Officer of Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 233 shares on June 18, 2026. The stock was trading at $93.23 at the time of the sale. The value of the transaction was not disclosed.
Mixed Activity Among Insiders
On the same day, Elizabeth also bought 263 shares for about $25,011. This reflects a mix of buying and selling activity among Mesa's executives. Brian Archbold, the Senior Vice President of Operations, also purchased 3,324 shares on June 18, valued at approximately $316,112.4. He later sold 2,516 shares on June 22. CFO John Sakys sold 2,756 shares on June 18, adding to the flurry of insider transactions.
Analysts Set New Price Targets
Wells Fargo maintained an Equal-Weight rating on Mesa Laboratories with a price target of $110.00 on August 14, 2026. This is an increase from a previous target of $94.00. The analysts see potential for stability in the stock, even as insiders engage in various transactions.
Stock Performance Context
Shares of Mesa Laboratories have seen volatility, trading below their 52-week high of $132.70. The stock's recent price of $93.23 is also lower than its 200-day moving average of $97.02. This could indicate challenges ahead, especially as the company prepares for its next earnings report on November 5, 2026.
What Mesa Laboratories, Inc. Does
Mesa Laboratories, Inc. develops and sells life sciences tools and quality control products. Its offerings include sterilization indicators and automated systems for protein analysis. As the company navigates through mixed insider activity, investors will be keen on how these transactions affect market perception.
What’s Next for Mesa Laboratories
Investors should watch for the upcoming earnings report on November 5, 2026, for insights into the company's financial health. Additionally, the recent insider trades may provide clues on executive sentiment regarding the company's future. Keep in mind that the reported trades reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Crennen Lyndsey Elizabeth's Form 4 filing on $MLAB (Jun 18, 2026). Find the original filing: MLAB Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts